Core Viewpoint - Universal Healthcare Group Limited ("Universal Healthcare", 2666.HK) has officially released its 2024 Environmental, Social, and Governance (ESG) report, showcasing its commitment to ESG responsibilities and addressing key concerns of stakeholders [1] ESG Strategy and Governance - In 2024, the company renamed its strategic committee to the Strategic and ESG Committee, marking a significant step in integrating ESG into its corporate strategy [1] - The company aims to align its development with public service, employee growth, environmental sustainability, and stakeholder collaboration [1] Healthcare Service Quality - Universal Healthcare has made significant advancements in specialized medical services, adding one national key specialty, three provincial clinical key specialties, and nine municipal clinical key specialties in 2024 [3] - The company has received over 100 quality-related awards and has made substantial improvements in hospital infrastructure, adding over 3,000 beds and 270,000 square meters of new construction [3] Digital Transformation and Innovation - The company is advancing its smart hospital initiatives and integrating digital solutions into its operations, with over 40 hospitals online and serving 41 million patients [4] - Universal Healthcare has achieved a 30% reduction in resource input and over 30% in total cost savings through centralized cloud deployment of approximately 200 application systems [4] Green Development Initiatives - The company is committed to green development, with new projects like the Xidian Hospital's outpatient and inpatient complex achieving a 16.97% energy-saving rate and reducing CO2 emissions by approximately 281.7 tons annually [5] - Universal Healthcare has successfully secured overseas ESG loans, with its green credit scale nearing 10 billion yuan by the end of 2024 [5] Employee Welfare and Rights - The company emphasizes employee rights and development, with a workforce of 22,885, of which 71.4% are women, and all employees receiving training [6] - Universal Healthcare has implemented a talent strategy to strengthen its workforce and ensure high-quality development [6] Social Responsibility and Community Engagement - The company has engaged in 12 charitable projects in 2024, assisting 699 patients and receiving recognition for its contributions to community health [7] - Universal Healthcare has been recognized for its long-term commitment to social welfare, including support for healthcare in remote areas [7] Recognition and Future Goals - In 2024, Universal Healthcare was ranked 63rd in CCTV's "Pioneer 100 ESG Listed Companies in China" and achieved a significant increase in its S&P Global ESG score [7] - The company aims to leverage its "medical, industry, and finance" synergy to enhance its ESG practices and contribute to sustainable development in China [8]

"五一"假期临近，国内市场即将迎来旅游餐饮消费高峰。海底捞后台数据显示，假期期间的用餐预订单 量正在快速上升，截至4月28日，全国门店已接到假期首日预订超2.5万桌。层出不穷的新场景、新玩 法、新产品，为消费者的假期带来了更多惊喜。(36氪) ...

Group 1 - The core viewpoint of the article highlights the performance of the CSI Hong Kong-Shanghai Biotech Theme Index, which reflects the overall performance of listed companies in the biotech sector from mainland China and Hong Kong [1][3] - The CSI Hong Kong-Shanghai Biotech Theme Index has shown an increase of 0.82% over the past month, 12.93% over the past three months, and 12.21% year-to-date [1] - The index consists of 50 sample companies involved in biopharmaceuticals, pharmaceuticals, and biotech services, with a base date of December 28, 2018, set at 1000.0 points [1] Group 2 - The top ten weighted companies in the index include: Heng Rui Medicine (13.16%), BeiGene (10.43%), WuXi AppTec (8.41%), Mindray Medical (7.71%), WuXi Biologics (5.15%), Innovent Biologics (4.82%), CanSino Biologics (3.91%), Shanghai Pharmaceuticals (2.74%), China National Pharmaceutical Group (2.45%), and Shanghai RAAS Blood Products (1.83%) [1] - The market share of the index holdings is distributed as follows: Hong Kong Stock Exchange 41.72%, Shanghai Stock Exchange 35.62%, and Shenzhen Stock Exchange 22.66% [1] Group 3 - In terms of industry composition, biopharmaceuticals account for 43.26%, chemical drugs for 25.78%, pharmaceutical and biotech services for 21.39%, and medical devices for 9.57% [2] - The index samples are adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December each year [2] - Special circumstances may lead to temporary adjustments to the index, including the removal of samples that are delisted or changes due to mergers, acquisitions, or other corporate actions [2]

Core Viewpoint - The China Securities Index for Hong Kong Stock Connect Medical Devices shows a recent decline, but has experienced significant growth over the past three months and year-to-date [1]. Group 1: Index Performance - The China Securities Index for Hong Kong Stock Connect Medical Devices reported a recent value of 1194.94 points [1]. - Over the past month, the index has decreased by 3.48%, while it has increased by 15.43% over the last three months and 12.63% year-to-date [1]. Group 2: Index Composition - The index is composed entirely of securities listed on the Hong Kong Stock Exchange, with a sample that includes various sectors classified under the China Securities Industry Classification Standard [2]. - The index's sample shows that medical consumables account for 79.10%, medical devices for 16.57%, and in vitro diagnostics for 4.34% [2]. Group 3: Index Adjustments - The index samples are adjusted biannually, specifically on the second Friday of June and December, with weight factors fixed until the next scheduled adjustment [2]. - In cases of special events affecting the index sample, such as delisting or mergers, adjustments will be made accordingly [2].

Group 1: Banking Sector Performance - Domestic banks are expected to report their Q1 earnings later this month, with preliminary reports aligning with market expectations [2][3] - Shenjing Bank's stock rose over 8%, indicating strong performance among domestic banks [3][4] - Citic Securities suggests that the banking sector will benefit from stable financial data, predictable dividend value, and relatively low valuation volatility, recommending an increase in allocation to this sector [2] Group 2: Nuclear Power Sector Developments - The State Council approved several new nuclear power projects, including the third phase of the Zhejiang Sanmen project and others in Guangxi, Guangdong, and Shandong, totaling five projects and ten new units [5] - China General Nuclear Power Corporation's stock rose over 2% following the announcement of these project approvals [5][6] Group 3: Stock Market Overview - The Hong Kong stock market showed mixed results, with the Hang Seng Index down 0.04% and the Hang Seng Tech Index up 0.12% [3] - Notable movements included JD.com rising over 2% and Meituan increasing by over 0.5%, while Lenovo Group fell over 1% [3]

截至4月28日收盘，安乐工程（01977.HK）报0.750港元，较上个交易日上涨2.74%，当日盘中最低价触 及0.720港元，创近一年新低。 本文源自：金融界 资金流向方面，当日主力流入3.848万港元，流出19.818万港元，净流出15.97万港元。 作者：港股君 安乐工程集团有限公司(以及其附属公司)('安乐工程'或'本集团')成立于1977年,是一家主要的电气和机械 工程和技术服务提供商,总部设在香港,在澳门、中国大陆、美国和联合王国开展业务。本集团为来自公 营及私营机构的广大客户提供多元及全面的电子工程及科技服务,包括建筑服务、环境工程、资讯、通 讯及建筑科技及升降机及自动梯。公司的母公司模拟控股有限公司于1995年成立,并于2019年在香港证 券交易所的主董事会上市(股票代码:1977)。公司的一些项目:港珠澳大桥工程服务。香港第一个有机资 源回收中心。昂船洲是世界上最大的化学强化初级废水处理厂之一,为香港提供经过加工和处理的水。 香港国际机场是世界上最好的机场之一,这是一个创新的过境生物鉴别系统。香港科学园的智能建筑,新 创意和创新需要最好的建筑系统。香港中央至中层的自动扶梯及人行道系统的翻新 ...

智通财经4月28日电，香港交易所信息显示，贝莱德在哔哩哔哩-W的持股比例于04月22日从5.05%降至 4.79%。 ...

去年营收166.57亿元，业务保持稳健发展，现金流充沛，在手订单充足。这就是神州控股(00861.HK)最 新交给市场的成绩单。 记者从公司处获悉，神州控股将于4月29日至30日第八届数字中国建设峰会期间，联合北京交通大学、 中国数联物流信息有限公司、中国星网数字科技有限公司，于4月30日共同举办"数字交通与物流分论 坛"，分享物流信息开放互联研究和实践经验，共促物流行业数智化转型，助推数字经济高质量发展。 面对AI技术革命，神州控股以"技术+场景+生态"模式抢占市场，在多个业务领域形成了可复制的典型 案例。依托国家技术发明奖一等奖成果转发的燕云DaaS进一步升级迭代为燕云Infinity，成为驱动公司 业务发展的核心引擎，也正在成为数据要素价值释放的工具。 在推进AI技术的场景化落地方面，公司在食品龙头企业打造的供应链控制塔，助力客户风险预警提示 项超90%，发货效率提升超20%、场内物流效率增幅超20%、成本节约超5%、耗材用量减少65%。 今年3月，神州控股旗下的神旗数码基于自身核心技术推出了融合DeepSeek私有化部署的端到端一体化 数据智能解决方案，助力客户打造AI好帮手，让客户在能够保持活跃能力 ...

智通财经APP获悉，4月28日，现制茶饮品牌沪上阿姨(02589)正式开启招股，至5月2日结束，拟全球发 售241.134万股H股，其中香港发售占10%，国际发售占90%，另有超额配股权不超过15%;发售价将不高 于每股发售股份113.12港元，且预期不低于每股发售股份95.57港元;每手30股，预期将于5月8日上午九 时正开始在联交所买卖。 财务数据方面，沪上阿姨同样亮眼。2022年-2024年，公司的营收分别为21.99亿元、33.48亿元和32.85 亿元;经调整净利润则分别为1.54亿元、4.16亿元和4.18亿元，整体势头强劲。 近期新茶饮赛道火热，头部品牌纷纷加速布局。此前业内人士分析提到，早前奈雪的茶、茶百道相继登 陆资本市场。今年以来，古茗、蜜雪冰城、霸王茶姬三家新茶饮品牌成功上市，给行业注入"强心剂"， 其中，蜜雪冰城更是创下港股IPO冻资新纪录，上市后股价一路飙升。霸王茶姬赴美上市成功后，新茶 饮赛道更是赚足了一波眼球。 此次招股，沪上阿姨引入2名基石投资者，合共认购约921.55万美元的发售股份，其中盈峰控股认购约 644.04万美元、华宝股份认购约277.51万美元。此次IPO，沪上阿 ...

李宁：一季度销售点（不包括李宁YOUNG）于整个平台之零售流水按年录得低单位数增长。 ...